{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:47:18Z","timestamp":1782258438930,"version":"3.54.5"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R326-A18938"],"award-info":[{"award-number":["R326-A18938"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R302-A17481"],"award-info":[{"award-number":["R302-A17481"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF21OC0072197"],"award-info":[{"award-number":["NNF21OC0072197"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Independent Research Fund Denmark"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02798-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:02:16Z","timestamp":1782255736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Thomas Landkildehus","family":"Lisle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0119-6033","authenticated-orcid":false,"given":"Emilie B\u00fclow","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamaila Munir","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-2647","authenticated-orcid":false,"given":"\u00d6zcan","family":"Met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-0297","authenticated-orcid":false,"given":"Rasmus O.","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-9605","authenticated-orcid":false,"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2798_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41392-026-02710-8","volume":"11","author":"MH Andersen","year":"2026","unstructured":"Andersen, M. H. Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond. Sig Transduct. Target Ther. 11, 130 (2026).","journal-title":"Sig Transduct. Target Ther."},{"key":"2798_CR2","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1158\/0008-5472.CAN-12-3507","volume":"73","author":"S Munir","year":"2013","unstructured":"Munir, S. et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res. 73, 1764\u20131776 (2013).","journal-title":"Cancer Res."},{"key":"2798_CR3","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","volume":"27","author":"JW Kjeldsen","year":"2021","unstructured":"Kjeldsen, J. W. et al. A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma. Nat. Med. 27, 2212\u20132223 (2021).","journal-title":"Nat. Med."},{"key":"2798_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405\u2013409 (2018).","journal-title":"Nature"},{"key":"2798_CR5","doi-asserted-by":"publisher","first-page":"e002500","DOI":"10.1136\/jitc-2021-002500","volume":"10","author":"M Bajor","year":"2022","unstructured":"Bajor, M. et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J. Immunother. Cancer 10, e002500 (2022).","journal-title":"J. Immunother. Cancer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02798-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:02:17Z","timestamp":1782255737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02798-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2798"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02798-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Biological material from healthy anonymized blood donors were acquired from Rigshospitalet, Copenhagen, Denmark. According to the Danish Law on Research Ethics \u00a7 14, section 3, the use of anonymized biological material does not require approval from an ethics committee. The PDL101-specific clone giving rise to the PDL101-TCR originated from a breast cancer patient enrolled in a clinical study at our center. Written informed consent was obtained before study enrollment, and the protocol was approved by the Scientific Ethics Committee for the Capital Region of Denmark (approval number: H-A-2009-013) in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"246"}}